LAVA Therapeutics NV Overview

LAVA Therapeutics NV Selling, General & Admin

Selling, General & Admin expenses for LVTX.

Quarterly SG&A Expenses

$5.31M

↑ 90.81% YoY

As of Sep 30, 2025

Annual SG&A Expenses (TTM)

$15.78M

↑ 46.1% YoY

Trailing 12 months ending Sep 30, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin